title: Treatment of Recalcitrant Cyclitic Neovascular Pupillary Membranes.
abstract: OBJECTIVE
  To describe a new approach for the treatment of cyclitic vascularized pupillary membranes.
  
  
  METHODS
  A retrospective interventional case series describing 3 patients undergoing a novel interventional treatment at a single institutional center.
  
  
  RESULTS
  This technique allows successful completion of laser membranectomy to create a pupillary aperture. This aperture resulted in improved vision and an enhanced ability to examine for and treat ischemic retinal disease.
  
  
  CONCLUSIONS
  This technique describes a new use for bevacizumab that enables the surgeon to treat recalcitrant and recurrent cyclitic vascularized pupillary membranes.
authors: Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.
authors: Alexander
authors: A
authors: Spratt
authors: Lauren S
authors: LS
authors: Blieden
authors: Sander R
authors: SR
authors: Dubovy
authors: Audina
authors: A
authors: Berrocal
authors: Richard K
authors: RK
authors: Lee
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000869:Anterior Eye Segment / Q000098:blood supply*; D000068258:Bevacizumab / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005124:Eye Abnormalities / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation; D053844:Lasers, Solid-State / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab